SCYNEXIS, Inc. is a pharmaceutical company. It is engaged in the discovery, development, and commercialization of anti-infectives to address unmet therapeutic needs. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. It also provides contract research and development services. SCYNEXIS, Inc. is headquartered in Durham, North Carolina.
| Revenue (Most Recent Fiscal Year) | $3.75M |
| Net Income (Most Recent Fiscal Year) | $-21.29M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 13.27 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.69 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -1044.49% |
| Net Margin (Trailing 12 Months) | -1030.04% |
| Return on Equity (Trailing 12 Months) | -53.47% |
| Return on Assets (Trailing 12 Months) | -32.86% |
| Current Ratio (Most Recent Fiscal Quarter) | 5.83 |
| Quick Ratio (Most Recent Fiscal Quarter) | 5.83 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.29 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.17 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.60 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.56 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Common Shares Outstanding | 39.02M |
| Free Float | 37.12M |
| Market Capitalization | $34.90M |
| Average Volume (Last 20 Days) | 0.20M |
| Beta (Past 60 Months) | 1.65 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 4.86% |
| Percentage Held By Institutions (Latest 13F Reports) | 54.37% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |